Amyloidosis, a special subtype of HFpEF caused by deposits of misfolded transthyretin in the extracellular space, has a poor prognosis, with median survival defined by the Gillmore classification between 24 and 69 months depending on levels of brain natriuretic peptide (BNP) above or below 3000 ng/l and estimated glomerular filtration rate below or above 45 ml/m [14]. Here, NPPB is linked to amyloidosis.